Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
E Palma - European Journal of Surgical Oncology (EJSO), 2017 - Elsevier
Background The optimal time interval between the end of neoadjuvant systemic therapy
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients.
C Omarini, G Guaitoli, S Noventa… - European Journal of …, 2016 - europepmc.org
Background The optimal time interval between the end of neoadjuvant systemic therapy
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
C Omarini, G Guaitoli, S Noventa, A Andreotti… - EUROPEAN JOURNAL …, 2016 - iris.unisr.it
The optimal time interval between the end of neoadjuvant systemic therapy (NST) and
breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit …
breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit …
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
C Omarini, G Guaitoli, S Noventa, A Andreotti… - EUROPEAN …, 2017 - iris.unimore.it
The optimal time interval between the end of neoadjuvant systemic therapy (NST) and
breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit …
breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit …
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
C Omarini, G Guaitoli, S Noventa, A Andreotti… - European Journal of …, 2017 - infona.pl
The optimal time interval between the end of neoadjuvant systemic therapy (NST) and
breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit …
breast surgery is still unclear. It is not known if a delay in surgery might influence the benefit …
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
C Omarini, G Guaitoli, S Noventa… - … journal of surgical …, 2017 - pubmed.ncbi.nlm.nih.gov
Background The optimal time interval between the end of neoadjuvant systemic therapy
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
C Omarini, G Guaitoli, S Noventa, A Andreotti… - European Journal of …, 2017 - ejso.com
Background The optimal time interval between the end of neoadjuvant systemic therapy
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …
(NST) and breast surgery is still unclear. It is not known if a delay in surgery might influence …